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Introduction
Cancer cell survival is dependent on sustained biosynthetic activities that are promoted by increased uptake of nutrients, such as glutamine. The energy production required for metabolism depends upon glycolysis rather than mitochondrial oxidative phosphorylation (OXPHOS), which can lead to lactate production from glucose (known as the Warburg effect) 1 . However, the functions of mitochondria in cancer cells remain intact 2 , allowing tricarboxyclic acid (TCA) cycle intermediates to "feed" biosynthetic pathways. Consequently, cancer cells can become "addicted" to glutaminolysis (a limiting step in the TCA cycle) because glutamine represents a major source of carbon molecules that can sustain tumor growth-facilitating metabolic pathways 3 . The gatekeeper enzyme of glutaminolysis is glutaminase (GA), which catalyzes the hydrolysis of glutamine to glutamate. In a second step, glutamate dehydrogenase (GDH) or transaminases produce α -ketoglutarate (αKG) from glutamate to "feed" the TCA cycle. In mammalian cells, the
GA family includes two isoforms encoded by GLS, kidney (K-type) glutaminase
(KGA) and glutaminase C (GAC), which are generally known as GLS1 4, 5 . Expression of KGA and GAC are increased in many types of cancers compared to normal tissues and the targeted inhibition of these enzymes has been shown to exert antitumor effects [6] [7] [8] [9] . Moreover, GLS2 encodes two liver (L-type) isoenzymes, LGA and GAB, which are collectively known as GLS2 [10] [11] [12] . GLS2 is a p53 target gene that carries out tumor suppressive functions 13, 14 .
We previously showed that targeting glutamine uptake can result in robust antileukemic responses in acute myeloid leukemia (AML), and we proposed the involvement of the mTORC1 signaling pathway downstream of glutamine addiction in this context 15 . However, little is known about mitochondrial metabolism in AML.
Primary AML cells have an increased mitochondrial mass and oxygen consumption rate compared to normal hematopoietic cells, and targeting mitochondrial translation has anti-leukemic effects 16 . The inhibition of mitochondrial respiratory chain complex I by metformin can reduce oxygen consumption and induce cytotoxicity in AML 17 .
Moreover, leukemic stem cells (LSCs), which are characterized by low reactive oxygen species (ROS), are "addicted" to OXPHOS rather than glycolysis, as
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Herein, we report that GLS1, especially the GAC isoform, is the major GA isoform expressed at the protein level in AML. Using both genetic and pharmacological approaches, we show that GLS1 inhibition can reduce the oxygen consumption rate (OCR), leading to cell proliferation inhibition and apoptosis. In a systemic mouse xenotransplantation model of AML, doxycycline-inducible GLS1 knockdown dramatically reduced AML development and extended survival. Finally, inhibition of glutaminolysis could activate a caspase-dependent mitochondrial apoptotic pathway and BCL-2 inhibition could synergize with compound CB-839, a GLS1 inhibitor. Our findings show that targeting glutaminolysis represents a novel strategy for exploiting the glutamine addiction of AML cells as a therapeutic modality.
Material and Methods

Primary human samples
Patients and healthy donors provided written informed consent in accordance with the Declaration of Helsinki and approval was obtained from the Cochin Hospital Institutional Ethic Committee. Bone marrow (BM) or peripheral blood (PB) samples with >70% blast cell content were obtained from 31 patients with newly diagnosed AML; patient characteristics are provided in Supplemental Table 1 . The CD34 + fraction, which is enriched in hematopoietic progenitor cells (HPCs), from BM healthy donors or umbilical cord blood were purified using MIDI MACS immunoaffinity columns (Milteny Biotech, Bergish Badgash, Germany).
Cell lines and reagents
We used MOLM-14, MV4-11, MOLM-13, OCI-AML2, OCI-AML3, HL60, K562, HEL, THP-1, U937, and KG1A AML cell lines; the main characteristics of these cells are listed in Supplemental was from Sigma-Aldrich. ABT-199 (GDC-0199) was from Selleck Chemical (Houston, TX).
Western blotting
Whole-cell extracts and western blotting were performed as previously described 15 .
Antibodies against PARP, cleaved-CASPASE-3, CASPASE-8, p21, and p27 were obtained from Cell Signaling Technology (Beverly, MA); anti-β-ACTIN and anti-GLS2 (HPA038608) antibodies from Sigma-Aldrich. Anti-GAC (19958-1-AP) and anti-GLS1
(20170-1-AP) antibodies were purchased from Proteintech (Manchester, UK). Anti-P85 antibody was raised in-house.
Proliferation assays
Cells were seeded at 5×10 4 /mL on day 0 and counted manually using Trypan Blue staining after 3, 5, and 7 days. 22 .
Apoptosis assay
Metabolic assays
Intracellular ATP levels were quantified using a luminescence-based cellular assay (CellTiter-Glo®; Promega, Madison, WI). Oxygen consumption was measured using a Seahorse XF96 extracellular flux analyzer as previously reported 23 . 24 .
Xenotransplantation of human leukemic cells in NSG mice
Adult mice (6-8 weeks old) were treated with 20mg/kg busulfan (Busilvex, Pierre 
Calculating of compounds synergistic effects
CB-839 was tested in combination with the BH3-mimetic ABT-199 using different doses. Relative induction of cell apoptosis was calculated for every dose combination. Using the Chalice software 26 , the response of the combination was compared to its single agents, against the widely used Loewe model for drug-withitself dose-additivity. Excess inhibition compared to additivity can be plotted as a full dose-matrix chart to visualize the drug concentrations where synergies occur.
Statistical analysis
All data are expressed as means with standard deviation. Statistically significant differences between experimental groups were determined using Student's t-test; *P<0.05, **P<0.01, and ***P<0.001. Data were analyzed using Prism software (GraphPad, La Jolla, CA). Independent experiments carried out in AML cell lines were each performed at least three times.
Results
Glutamine controls mitochondrial OXPHOS in AML
We previously reported that the inhibition of glutamine uptake exerts anti-leukemic effects in AML 15 . In our present study, we extended this previous observation to a panel of 11 AML cell lines that were cultured with or without glutamine. Glutamine removal significantly induced apoptosis in all of the AML cell lines tested ( Figure 1A ).
Because glutamine "feeds" the TCA cycle in many cancers, we hypothesized that glutamine removal-induced apoptosis that resulted from TCA cycle inhibition. For personal use only. on October 24, 2017. by guest www.bloodjournal.org From observed a significant reduction in the O 2 consumption rate (OCR) using a Seahorse XF96 analyzer, which indicates OXPHOS inhibition in glutamine-deprived AML cells ( Figure 1C ). This effect on OCR was observed both at baseline and after injecting CCCP, an uncoupler that raised OCR to it maximal rate. The effect of glutamine deprivation on OCR could be blunted by co-incubation with α KG in all of these cell lines ( Figure 1D ). These findings indicate that AML cells are "addicted" to the glutamine-dependent TCA cycle.
GAC protein is prominently expressed in AML and modulates the OCR
We measured the protein expression of KGA, GAC, and GLS2 in 26 primary AML We then tested the effects of three GSL1 inhibitors on the OCR. Compound CB-839 24 and BPTES 27 can inhibit both isoforms, whereas compound 968 is considered to be GAC-specific 8 . In OCI-AML2 cells, CB-839, but not BPTES or compound 968, could inhibit the baseline OCR ( Figure 2C ). After mitochondrial uncoupling by CCCP, both CB-839 and BPTES more robustly reduced OCR compared with compound 968.
Similar results were observed in MOLM-14 cells ( Figure S2D ). In addition to OCR modulation in OCI-AML2 cells, CB-839 and BPTES, but not compound 968, reduced the intracellular concentrations of glutamate, malate, and citrate, suggesting that these compounds are useful tools to target glutaminolysis and the TCA cycle ( Figure   2D ). In OCI-AML2 cells, α KG could reverse CB-839-induced inhibition of OCR at both baseline and after decoupling, indicating that OCR suppression was related to 
GLS1 controls AML survival by modulating the TCA cycle
We observed apoptosis, as indicated by Annexin V staining, in five different AML cell lines upon GLS1 knockdown, particularly in OCI-AML2 cells ( Figure 4A ). Apoptosis was reduced in cells co-incubated with αKG ( Figure S4A ). In normal CD34 + HPCs, GLS1 knockdown did not result in significant apoptosis ( Figure 4B ). To test the in vivo anti-leukemic potential related to the inhibition of glutaminolysis, we generated a systemic xenotransplantation AML model in NSG mice injected with MOLM-14 or OCI-AML3 cell lines expressing either the shGLS1#5 or a control shRNA. Dox-
induced GLS1 knockdown prevented AML growth in both cell lines, reduced splenomegaly development in OCI-AML2 and dramatically extended mouse survival ( Figures 4C-D) . The anti-leukemic activity that resulted from GAC inhibition by CB-839 was then tested in 11 AML cell lines; compound CB-839 induced apoptosis in 7 of these cell lines ( Figure 4E ). This pro-apoptotic activity could be fully reversed by co-incubation with αKG in OCI-AML2 and HL-60 cells ( Figure 4F) . Similarly, ectopic expression of super-active GAC K320A mutant protein preserved cell viability in CB-839-treated OCI-AML2 cells ( Figure 4G ). Compound CB-839 also induced apoptosis in primary AML samples, but not in normal CD34 + HPCs ( Figure 4H ). These findings indicated that GLS1 inhibition targets leukemic, but not normal hematopoietic cells.
GLS1 inhibition induces mitochondrial apoptosis and sensitizes leukemic cells to priming with ABT-199
In OCI-AML2 cells, GLS1 inhibition was correlated with mitochondrial depolarization, transporter. This process is critical for activating the mTORC1 signaling pathway via the Ragulator-Rag complex that translocates mTORC1 to lysosomal membranes which is the key event in amino acid signaling to mTORC1 30, 31 . Glutamine catabolism begins by converting glutamine to glutamate in reactions catalyzed by GA that either donate an amide nitrogen molecule to biosynthetic pathways or release it as ammonia. Glutamate, the product of a GA reaction, is the most important source of αKG, which is a major TCA intermediate and the substrate for dioxygenases, which include the prolyl hydroxylases, histone demethylases, and TET2 5-methylcytosine hydroxylase. The main function of αKG is to sustain OXPHOS through the TCA cycle, so it represents an important source of energy. However, glutamate also provides precursors for glutathione production, which contribute to maintaining the oxidative status of cells. It is also a source of amino groups for non-essential amino acids, such as alanine, aspartate, glycine, and serine. Finally, glutamine-derived nitrogen is a component of hexosamine for N-glycosylation reactions and can act to control nucleic acid synthesis 32 .
In AML, glutamine controls mTORC1 activity via the amino acid pathway, and glutamine depletion blocks protein synthesis 15 . In addition to mTORC1, other metabolic pathways that are dependent on glutamine might account for the antileukemic activity that results from glutamine deprivation. In our present report, we
show that AML cells are generally "addicted" to glutamine and dependent upon mitochondrial OXPHOS for their survival. The critical role of glutamine as a limiting step in the TCA cycle, which is supported by the pro-survival activity of the TCA cycle
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From intermediate αKG in glutamine-starved AML cells, prompted us to study the impact of glutaminolysis on AML cell proliferation and survival. In accordance with observations made in other types of cancer, we found that GLS1, particularly the GAC isoform, was the most frequently and strongly expressed GA isoform in AML cells 7 . GLS1 expression levels were found to be within the same range across AML samples, and also in comparison to normal HPCs, indicating that GLS1 overexpression is most likely not a leukemic feature, in contrast to other cancer models 33 .
Three GLS1 inhibitors are currently available: BPTES, compound 938, and compound CB-839. Among these compounds, CB-839 is currently being administered to humans in phase I clinical trials for solid tumor, lymphoid, and myeloid malignancies (NCT02071862, NCT02071888, and NCT02071927).
Compound 968 was identified through a small molecule screening effort using
RhoGTPase-transformed fibroblasts, and its activity has been reported to be directed against GAC, but not KGA 8 . In our present study, compound 968 had no effect on glutaminolysis, as it did not reduce the measured OCR or impact TCA metabolite intermediates in AML. Moreover, compound 968 induced mild apoptosis in AML cell lines, which was not rescued by αKG, strongly suggesting that these functional effects were related to off-target effects (data not shown). By contrast, both BPTES and CB-839 affected the TCA cycle and OCR. Strikingly, the pro-apoptotic activity of the clinical candidate molecule CB-839 was blunted by both αKG co-treatment and the expression of a GAC K320A super-active mutant. These findings, which we obtained using a pharmacological approach, were corroborated by the effects of GLS1 knockdown by two distinct hairpin sequences in AML cell lines. Based on these data, we conclude that specific GLS1 blockade-particularly using compound CB-839-efficiently eradicates AML cells in a pre-clinical setting.
In normal hematopoiesis, metabolism has recently emerged as being critically involved in survival, proliferation, and stem cell lineage specification. Normal murine HSCs exhibit high rates of glycolysis that are supported by the abundant expression of pyruvate dehydrogenase kinase (PDH), which suppresses mitochondrial glucose oxidation in a process that is essential to self-renewal capacities 34 . It has also been shown that mice deficient in glycolysis enzymes, such as M2 pyruvate kinase (PKM2) or lactate dehydrogenase A (LDHA), have hematopoietic defects with abnormal 1 3 progenitor functions and, in the case of LDHA knockdown, HSCs abnormalities with impaired long-term reconstitution capacities 35 . Glutamine metabolism also regulates human HSC lineage specification, as it was demonstrated that the SLC1A5 glutamine transporter is required for erythroid specification by regulating de novo nucleotide biosynthesis 36 . From the perspective of the therapeutic applications of GSL1-targeting in humans, we investigated the potential toxicity that results from GLS1 inhibition during normal hematopoiesis. Homozygous GLS1 deletion is lethal during the first postnatal day because of neurological disorders 37 . However, the impact of GLS1 knockout on blood formation has not yet been reported. In normal immature CD34 + hematopoietic progenitor cells, our data presented here show that GLS1 inhibition did not translate into reduced cellular proliferation and/or survival.
Moreover, orally administered CB-839 did not modify blood cell count parameters in a mouse xenotransplantation model of breast cancer 24 . The results of ongoing clinical trials will likely confirm the favorable therapeutic index of GLS1-targeting that we found in our preclinical analysis.
We further showed from our present analyses that GLS1 inhibition-induced apoptosis triggered caspase activation, which largely involved the intrinsic mitochondrial apoptotic pathway. While the molecular mechanism leading from GLS1 disruption to mitochondrial membrane depolarization remains incompletely characterized, this pattern of caspase activation might suggest new therapeutic combinations. Indeed, BH3-mimetic compounds, such as ABT-199 or ABT-737, specifically act on BCL-2 and lead to subsequent cytochome C release and mitochondrial apoptosis via activate Bak/Bax dimer formation 38 . In primary AML LSCs, high expression of BCL-2 mostly supports OXPHOS metabolism and correlates with a high sensitivity to BCL-2 inhibition in this cellular compartment 18 . Our current findings regarding the synergic anti-leukemic activity of combined BCL-2 (using ABT-199) and GLS1 (using CB-839) inhibition open the possibility of testing this strategy in clinical trials.
In conclusion, AML cells have a unique sensitivity to glutaminolysis inhibition that results from the sustained suppression of the TCA cycle and OXPHOS activity. Our analysis of the molecular mechanisms of apoptosis downstream of GLS1 inhibition also provide insights into the molecular basis for the synergistic effects of a 1 4 combination of GLS1 and BCL-2 inhibitors, which could represent a novel therapeutic strategy for AML.
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Figure 3
A. OCI-AML2 and MOLM-14 shGLS1#5 leukemic cells were seeded at 5×10 
